Seeking more efficient drug development, pharmaceutical giants and startups are encouraging AI fluency and in some cases ...

With the rising adoption of checkpoint inhibitors and combination therapies, BAVENCIO's market growth is driven by expanding indications and strategic partnerships. However, competition from ...

DelveInsight's "BAVENCIO Market Size, Forecast, and Market Insight Report" highlights the details around BAVENCIO, a human ...

We recently compiled a list of the 10 Most Undervalued US Stocks to Buy According to Hedge Funds. In this article, we are ...

Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn ...

We recently published a list of 10 Most Undervalued High Quality Stocks to Buy According to Analysts. In this article, we are ...

Great investments are even better and more fruitful when you can buy them at a discount. Lots of investors enjoy keeping an ...

Vaccinex, Inc. (OTC: VCNX) ("Vaccinex" or the "Company"), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative ...

2/26，在上市十多年后，Keytruda（帕博利珠单抗）继续实现卓越的年增长，但默沙东（Merck & Co.）认为其黄金时期即将结束，而这一结束的时刻比该产品专利到期时间还要提前几个月。 在本周的一份美国证券文件中，默沙东承认，其癌症免疫疗法重磅药物可能会在明年被美国政府选中进行“定价谈判”，根据《通货膨胀削减法案》（IRA）。默沙东预计，经过谈判的价格将于2028年1月1日起生效，此后“Ke ...

According to Halozyme, the new version of Keytruda infringes on its patents, the report said. USAID cuts put tuberculosis response in peril, WHO says The Trump administration's decision to pause U.S.